Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03312972 · ClinicalTrials.gov registry record · NA
Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy
A NA study of Locally Recurrent Prostate Cancer, sponsored by Loyola University.
- Active
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT03312972: Active NA study of Locally Recurrent Prostate Cancer, sponsored by Loyola University.
NCT03312972 is a NA study of Locally Recurrent Prostate Cancer that is active but no longer recruiting, run by Loyola University. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03312972, a NA study of Locally Recurrent Prostate Cancer, is active but no longer recruiting, sponsored by Loyola University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This purpose of this study is to evaluate the safety and effectiveness of a technique called focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back in the prostate after prior radiotherapy. The study will examine the safety and efficacy of the treatment. The type of radiation that participants in this research will receive is targeted directly at the areas of the prostate where recurrent disease is evident, while avoiding treatment of the normal appearing prostate. This involves the placement of a radioactive material in the affected area of the prostate temporarily, where it remains for a short period of time, and then is subsequently removed using a minimally invasive technique called HDR Brachytherapy.
Primary Outcome
The primary outcome in this study is the number of acute or chronic grade 3-5 toxicities as described by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Conditions Studied
Interventions
- RADIATION HDR Brachytherapy
Study Locations (2)
Illinois
- Loyola University Medical Center - Maywood
Virginia
- University of Virginia School of Medicine - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2026-07-31 |
| Phase | NA |
What the registry record for NCT03312972 still lists
NCT03312972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Locally Recurrent Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which HDR Brachytherapy is the first listed.
NCT03312972 reports a single indexed study location in Illinois, Virginia.
Frequently Asked Questions
What is clinical trial NCT03312972 about?
NCT03312972 is a clinical study titled "Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy". This purpose of this study is to evaluate the safety and effectiveness of a technique called focal high-dose-rate (HDR) brachytherapy as treatment for prostate cancer that has come back in the prostate after prior radiotherapy. The study will examine the safety and efficacy of the treatment. The typ...
What is the current status of trial NCT03312972?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2017-08-28. Estimated completion is 2026-07-31.
What conditions does trial NCT03312972 study?
This clinical trial studies the following conditions: Locally Recurrent Prostate Cancer.
What interventions are being tested in trial NCT03312972?
The interventions under investigation include: HDR Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT03312972?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03312972 being conducted?
This trial has 2 study locations across Illinois, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03312972's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI